{
    "2021-06-06": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)",
                "features": {
                    "keywords": [
                        "Novartis",
                        "iptacopan",
                        "Phase II",
                        "study",
                        "primary endpoint",
                        "IgA nephropathy",
                        "IgAN"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}